Jane Street Group LLC Purchases 89,198 Shares of Certara, Inc. (NASDAQ:CERT)

Jane Street Group LLC lifted its stake in shares of Certara, Inc. (NASDAQ:CERT - Free Report) by 60.5% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 236,591 shares of the company's stock after purchasing an additional 89,198 shares during the quarter. Jane Street Group LLC owned 0.15% of Certara worth $2,520,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in CERT. Kopion Asset Management LLC boosted its holdings in Certara by 46.0% in the 4th quarter. Kopion Asset Management LLC now owns 555,643 shares of the company's stock valued at $5,918,000 after purchasing an additional 175,005 shares during the period. Principal Financial Group Inc. lifted its position in Certara by 3.1% during the fourth quarter. Principal Financial Group Inc. now owns 531,445 shares of the company's stock valued at $5,660,000 after purchasing an additional 15,739 shares during the last quarter. Vontobel Holding Ltd. purchased a new position in Certara in the 4th quarter worth approximately $1,295,000. First Trust Advisors LP purchased a new stake in shares of Certara during the 4th quarter valued at $140,000. Finally, Barclays PLC grew its position in Certara by 198.3% in the third quarter. Barclays PLC now owns 70,525 shares of the company's stock worth $825,000 after acquiring an additional 46,880 shares in the last quarter. Institutional investors own 73.96% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the company. William Blair reiterated a "market perform" rating on shares of Certara in a report on Thursday, February 27th. Barclays raised shares of Certara from an "equal weight" rating to an "overweight" rating and raised their price target for the stock from $11.00 to $14.00 in a report on Thursday, May 8th. JMP Securities restated a "market perform" rating on shares of Certara in a report on Tuesday, May 6th. TD Cowen started coverage on Certara in a research report on Thursday, February 27th. They set a "buy" rating and a $16.00 price objective for the company. Finally, Stephens reissued an "overweight" rating and issued a $17.00 target price on shares of Certara in a report on Thursday, February 27th. Three equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, Certara has a consensus rating of "Moderate Buy" and a consensus price target of $15.67.

Certara Stock Performance

Shares of NASDAQ:CERT traded down $0.31 during trading on Tuesday, hitting $11.47. The company's stock had a trading volume of 136,717 shares, compared to its average volume of 1,740,126. The company has a 50-day moving average of $11.73 and a 200-day moving average of $11.75. Certara, Inc. has a 12 month low of $8.64 and a 12 month high of $17.75. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.86 and a quick ratio of 2.86. The firm has a market cap of $1.86 billion, a price-to-earnings ratio of -57.40, a P/E/G ratio of 9.29 and a beta of 1.57.

Certara (NASDAQ:CERT - Get Free Report) last announced its earnings results on Monday, May 5th. The company reported $0.14 EPS for the quarter, topping analysts' consensus estimates of $0.10 by $0.04. The company had revenue of $106.00 million for the quarter, compared to analysts' expectations of $104.44 million. Certara had a positive return on equity of 3.43% and a negative net margin of 8.34%. Certara's revenue for the quarter was up 9.7% compared to the same quarter last year. During the same period last year, the firm earned $0.10 EPS. On average, sell-side analysts expect that Certara, Inc. will post 0.28 earnings per share for the current year.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.